Thesis (Ph. D.)--Brigham Young University. Dept. of Microbiology and Molecular Biology, 2007. / Includes bibliographical references (p. 75-82).

Universiẗat, Diss., 2006--Würzburg.

Made available in DSpace on 2014-06-11T19:32:13Z (GMT). No. of bitstreams: 0 Previous issue date: 1986Bitstream added on 2014-06-13T20:42:59Z : No. of bitstreams: 1 barraviera_b_dr_botfm.pdf: 3578174 bytes, checksum: 1a21940039bc694d01cadb7e41e07ecf (MD5) / Com o objetivo de contribuir para o esclarecimento de alguns pontos obscuros nas relações existentes entre a atividade da via das pentoses e a redução das metahemoglobina pela cistamina, em indivíduos normais e doentes com malária, causada pelo Plasmodium falciparum, bem como a relação entre a atividade da glutationa redutase e o efeito do tratamento pela riboflavina, foi proposto novo método de pesquisa pouco dispendioso, simples e que permitisse aplicação em estudo de campo. Com o método padronizado, foram estudados indivíduos normais de Botucatu, Amazônia e Anhembi e doentes com malária causada pelo Plasmodium falciparum, atendidos em Humaitá... / Click electronic access below.

Orientador: Paulo Eduardo de Abreu Machado / Resumo: Com o objetivo de contribuir para o esclarecimento de alguns pontos obscuros nas relações existentes entre a atividade da via das pentoses e a redução das metahemoglobina pela cistamina, em indivíduos normais e doentes com malária, causada pelo Plasmodium falciparum, bem como a relação entre a atividade da glutationa redutase e o efeito do tratamento pela riboflavina, foi proposto novo método de pesquisa pouco dispendioso, simples e que permitisse aplicação em estudo de campo. Com o método padronizado, foram estudados indivíduos normais de Botucatu, Amazônia e Anhembi e doentes com malária causada pelo Plasmodium falciparum, atendidos em Humaitá... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: Click electronic access below. / Doutor

The Plasmodium falciparum parasite is the causative agent of the most severe form of malaria. The increase in resistance against the majority of antimalarial compounds underpins the need for the development of new antimalarial compounds, targeting novel biological activities of the parasite. As the P. falciparum parasite develops through its life cycle stages, the parasite is exposed to different environments, resulting in both strategy-specific differences between the asexual (proliferation) and gametocyte (differentiation) stages, as well as stage-specific (i.e. ring – schizont stages; stage I - V gametocytes) differences within each strategy. These strategy- and stage-specific differences might be supported by the presence of different membrane transport proteins (MTPs) in the asexual and gametocyte stages. P. falciparum-encoded MTPs (permeome) are promising novel drug targets because they are specific to P. falciparum and essential for the survival of the P. falciparum parasite as these proteins mediate the uptake and removal of metabolites and waste products. However, to propose parasite-encoded MTPs as potential novel drug targets in the asexual and gametocyte stages, the presence of these MTPs in these stages should be investigated. The P. falciparum-encoded permeome is well characterised in the asexual stages. However, limited knowledge is available about the permeome in the gametocyte stages. Therefore, to address this knowledge gap, the strategy- and stage-specific expression of the entire complement of parasite-encoded MTPs were investigated in the asexual and gametocyte stages to infer the presence of MTP transcripts in the absence of biochemical uptake data. The transcript expression of the permeome revealed strategy-specific expression, with the entire permeome expressed during asexual stages, as expected, given the metabolic adaptations that support the high proliferation rate. By contrast, the gametocyte stages that are undergoing sexual differentiation towards transmission, as opposed to active proliferation, less than half of the permeome were expressed, indicating a reduced range of MTPs active in the gametocyte stages. Subsequently, stage-specific expression of the permeome was investigated by correlating stage-specific metabolic processes that occur within the asexual and gametocyte stages, to the expression profiles of MTP genes involved in these processes. Most of the MTPs involved in these processes showed stage-specific expression, with a few MTP genes showing no stage-specific expression within the asexual and gametocyte stages, respectively. When comparing the stage-specific expression between the asexual and gametocyte stages, it was observed that during the gametocyte stages, there was an absence of some MTPs (decreased expression) that were expressed during the asexual stages, suggesting that the gametocyte stages require only certain metabolites to maintain the investigated metabolic processes. In conclusion, these expression profiles of the permeome in the asexual and gametocyte stages suggest the differential expression of the permeome in these stages. The data presented in this study provides the first complete evaluation of expression of the permeome across P. falciparum asexual and gametocyte stages and serves as a blueprint for future biochemical investigations of transport in these stages, thereby providing a foundation for identifying novel MTP drug targets in future drug development programmes. / Dissertation (MSc)--University of Pretoria, 2018. / NRF / Biochemistry / MSc / Unrestricted

A hallmark trait of P. falciparum malaria is sequestration, in which parasite infected erythrocytes (IEs) adhere to the vasculature, causing organ failure and death. Current antimalarials only kill the parasites, necessitating development of anti-adhesion drugs. Using our two-step approach, we can efficiently screen for anti-adhesion small molecules. Screenings of 75libraries using Bio-Plex 200 identified the most active TPI libraries, which were deconvoluted to single compounds. Screenings library TPI 1319 yielded 3 inhibiting non-optimized compounds, each of which inhibits binding between two receptors, CSA and ICAM1, and their binding PfEMP1 domains. Two compounds deconvoluted from TPI 2103 prevent binding between PfEMP1 and ICAM1. Cytoadhesion assays with live IEs support the results seen with Bio-Plex, with best hits showing inhibition below 200 nM. Cytotoxicity testing of active compounds showed minimaltoxicity. Identified hits appear to be amenable to Structure Activity Relationship studies to develop powerful anti-adhesion drugs to treat severe malaria. / Includes bibliography. / Thesis (MS)--Florida Atlantic University, 2021. / FAU Electronic Theses and Dissertations Collection

Includes bibliographical references / [No subject] Malaria infection caused by the apicomplexa pathogen Plasmodium falciparum has a high rate of resistance to existing anti-malarial drugs. The World Health Organisation recommended interventions are unlikely to eliminate the growth of resistance and it would therefore be prudent to continue the search for new drug targets for the continued combatting of malaria. Plasmodium falciparum is parasitic on the host for its metabolites and therefore inhibiting the transportation of glutamine from the host, has long been considered a potential strategy for combating the spread of infection. The recently sequenced Plasmodium falciparum genome has however shown that pathways for independent survival are also conserved. Therefore, combating the spread of Plasmodium falciparum in the human host, in addition to inhibiting the transportation of glutamine, will also require the inhibition of the de novo expression of essential amino acids within the Plasmodium falciparum cell. This could be achieved by inhibiting the glutamine synthetase gene, which is an essential step in the tri-carboxylic acid cycle.

Introducción: Malaria representa una emergencia médica debido a la posible complicación y muerte del paciente cuando este no fue tratado apropiadamente. Malaria severa y/o complicada (MSC) es causada casi exclusivamente por Plasmodium falciparum. Uno de los factores de riesgo asociado con MSC es el tratamiento inadecuado de los casos de malaria no complicada (MNC). Objetivos: Se genotipificó a los genes dihidrofolato reductasa (Pfdhfr) y dihidropteroato sintasa (Pfdhps) en muestras de 60 pacientes con MSC. La resistencia al tratamiento combinado sulfadoxina-pirimetamina (SP) es causado principalmente por mutaciones puntuales en esos genes Diseño de estudio: Los pacientes con MSC de este estudio fueron enrolados durante el brote de malaria de 1998, cuando SP era la primera línea de tratamiento. Materiales y métodos: Se usó el método de secuenciamiento de Sanger para la identificación de los polimorfismos en el gen Pfdhfr y los métodos PCR-RFLP y PCR alelo-específico para el gen Pfdhps. Resultados: Se encontró que el 84% de las muestras tenían el genotipo del parásito cuádruple mutante N51I/S108N/I164L/inserción repetición Bolivia, y el 16% restante el genotipo mutante simple S108N. Con respecto al gen Pfdhps, encontramos cuatro genotipos, siendo el triple mutante A437G/K540E/A581G el más frecuente (78%). Conclusiones: Observamos que las mutaciones I164L de Pfdhfr y K540E de Pfdhps en los casos de MSC fueron más del doble de frecuente comparado con los reportes publicados en casos de MNC en la misma área y periodo de estudio. / --- Introduction: Malaria represents a medical emergency because it may rapidly progress to complication and death without prompt and appropriate treatment. Severe and/or complicated malaria (SCM) is almost exclusively caused by Plasmodium falciparum. One of the risk factors associated with SCM is an inappropriate treatment of the noncomplicated malaria (NCM). Objectives: We genotyped the dihydrofolate reductase (Pfdhfr) and dihydropteroate synthase (Pfdhps) genes from 60 SCM patients. Resistance to SP in P. falciparum is caused mainly by specific mutations at those genes. Study design: SCM patients of this study were enrolled during the malaria outbreak in 1998, when sulfadoxine/pyrimethamine (SP) was the first line of treatment. Material and methods: We used a Sanger sequencing approach for the identification of polymorphisms at Pfdhfr gene codons, and in the case of Pfdhps gene we used a PCRRFLP and PCR allele-specific methodology. Results: We found that 84% of samples harbored a quadruple mutant genotype N51I/S108N/I164L/insertion Bolivia repeat, and the left 16% of the sample contained an infection with a simple mutant genotype (S108N). Regarding the Pfdhps gene, we found four genotypes, the triple mutant genotype A437G/K540E/A581G was the more frequent (78%). Conclusions: We observed that the mutations I164L and K540E, known as highly predictor to SP resistance, in this group of patients with SCM were twice of frequency of the mutations from patients with NCM from published reports, also in the same area and period of study. / Tesis

Malaria is arguably one of the most overwhelming infectious diseases throughout the world's existence. The most virulent parasite, Plasmodium falciparum, has a redundancy of invasion proteins, allowing it to switch between different receptors on the host red blood cell. These invasion proteins are stored in the apical organelles, the rhoptries and micronemes, but very little is known about how newly synthesized proteins are transported to these organelles. The hypothesis in this study was that a common protein is involved in trafficking invasion proteins from the trans-Golgi network and PfSORTILIN was investigated as a potential escorter protein. The CCys domain of PfMAEBL, a rhoptry protein, and the prodomain of PfAMA-l, a microneme protein, have been implicated in trafficking to the apical organelles. These domains and the VPS 10 domain of PfSORTILIN were cloned into expression vectors encoding a GST- or Histag. Recombinant proteins were expressed in E. coli and purified by affinity chromatography on glutathione- or Ni-particles. In vitro binding assays were performed, which showed that PfSORTILIN VPS 10 bound to PfMAEBL ccys but not to the PfAMA-1 prodomain, suggesting that PfSORTILIN is a rhoptry protein escorter and is not involved in microneme trafficking. To identify novel binding partners of PfSORTILIN VPS 10, the protein was biopanned against a P. falciparum phage display library. No binding partners were identified, most likely because the library is not schizont-stage specific, which is when PfSORTILIN and invasion proteins are predominantly expressed. The results from this study were integrated with other studies and a trafficking model for PfMAEBL was proposed. This study enhances our knowledge of trafficking pathways and suggests that PfSORTILIN may serve as a common rhoptry protein escorter. / MT 2019

Malaria remains a global health problem, despite over a century of efforts towards control and prevention. It is responsible for over 2 million deaths a year. Plasmodium falciparum, the protozoan parasite that causes malaria, presents quite an unexplored field of study, significant both for the purposes of understanding the complex life cycle of the parasite, and for identifying novel and unique targets for anti-malarial therapy. Cyclin-dependent kinases. (CDK.s) play a number of crucial roles in the progression of the cell cycle such as regulating the onset of DNA replication and entry into mitosis. Plasmodium falciparum protein kinase 5, PfPK5, manifests characteristics of eukaryotic CDKs. It is a serine/threonine kinase, has 60% amino acid identity to eukaryotic cyclin-dependent kinase cdc2, and shares the mechanism of activation with CDKs. To establish if PfPK5 indeed is the major cell cycle regulatory kinase, as well as to expand our knowledge about the signaling networks of the parasite, it is necessary to identify proteins that interact with the kinase, such as its putative substrates. Currently, only one Plasmodium falciparum protein is known to interact with PfPK5 - its cyclin partner, Pfcycl. Identifying substrates of PfPKS is a particularly important research endeavor since it would provide insight into the yet unknown downstream signaling pathways of PfPK5. It is likely that pathways unique to Plasmodium falciparum will be found, which may be specifically targeted for anti-malaria therapy. A potential substrate of Plasmodium falciparum cell cycle regulatory kinase PfPK5 has been identified. The new protein, which we call SPOK, was identified by screening a phage display cDNA library. Since SPOK is a large protein of approximately 140kDa, a domain containing a tandem CDK/cdc2 phosphorylation motif of SPEK (single amino acid code, S/TPXK/R) was expressed in E.coli. Our results show that this domain of SPOK is indeed phosphorylated in vitro by PfPK5. This raises the possibility that SPOK could be an in vivo substrate of PfPK5 and may play a role in regulating the cell cycle of the parasite.